Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Receivables - Net (2018 - 2024)

Historic Receivables - Net for Abvc Biopharma (ABVC) over the last 10 years, with Q3 2024 value amounting to $1529.0.

  • Abvc Biopharma's Receivables - Net fell 6.54% to $1529.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $1529.0, marking a year-over-year decrease of 6.54%. This contributed to the annual value of $839983.0 for FY2023, which is 1091.18% up from last year.
  • According to the latest figures from Q3 2024, Abvc Biopharma's Receivables - Net is $1529.0, which was down 6.54% from $1530.0 recorded in Q2 2024.
  • Abvc Biopharma's Receivables - Net's 5-year high stood at $839983.0 during Q4 2023, with a 5-year trough of $1529.0 in Q3 2024.
  • Its 5-year average for Receivables - Net is $225176.7, with a median of $159712.0 in 2020.
  • In the last 5 years, Abvc Biopharma's Receivables - Net skyrocketed by 25614.47% in 2021 and then plummeted by 9876.75% in 2024.
  • Quarter analysis of 5 years shows Abvc Biopharma's Receivables - Net stood at $159712.0 in 2020, then soared by 75.75% to $280692.0 in 2021, then soared by 169.81% to $757343.0 in 2022, then rose by 10.91% to $839983.0 in 2023, then plummeted by 99.82% to $1529.0 in 2024.
  • Its last three reported values are $1529.0 in Q3 2024, $1530.0 for Q2 2024, and $1530.0 during Q1 2024.